PARTUM
The PARTUM Trial: A pragmatic non-inferiority trial comparing low-dose aspirin versus usual care low-molecular-weight heparin for postpartum VTE preventionThe PARTUM Trial: A pragmatic non-inferiority trial comparing low-dose aspirin versus usual care low-molecular-weight heparin for postpartum VTE prevention
"Postpartum venous thromboembolism (VTE: deep vein thrombosis [DVT] or PE) carries significant morbidity, and PE is a leading cause of maternal mortality. Conversely, bleeding is a major cause of severe maternal morbidity. Postpartum VTE prevention strategies frequently include low-molecular-weight heparin (LMWH) injections despite little evidence. LMWH prophylaxis is overused in many countries and imposes cost, pain, and bleeding risk. There remains a critical and well-defined knowledge gap regarding the optimal prophylaxis strategy to prevent postpartum VTE.
The PARTUM trial will close this gap and is a non-inferiority randomised trial of 8,805 participants in 11 countries to assess if 6 weeks (wks) of low-dose aspirin (ASA) is non-inferior to usual care LMWH regimens to prevent VTE in postpartum patients at risk of VTE. We request funds to recruit 1,850 patients in 3 European countries.
Population: Adult | Intervention type: Interventional
